摘要
目的分析某肿瘤医院乳腺癌内分泌治疗药物的应用情况与发展趋势,促进合理用药。方法统计某肿瘤医院2012年至2013年各类乳腺癌内分泌治疗用药总金额和各类品种的用药金额及所占比例、用药频度(DDDs)与日均费用(DDDc),计算销售金额排序/DDDs排序位次比值进行分析。结果芳香化酶抑制剂和抗雌激素类药品占主导用药地位。DDDs排序前5位药品是他莫昔芬、来曲唑(进口)、阿那曲唑(进口)、醋酸戈舍瑞林缓释植入剂、阿那曲唑(重庆)。结论该肿瘤医院乳腺癌内分泌治疗用药基本合理。
Objective To analyze the hospital endocrine therapy on breast cancer medication and trends, to promote rational drug use. Methods Statistics in a cancer hospital from 2012 to 2013 the total amount of all types of endocrine therapy in breast cancer treatment and various species of the amount and proportion of medication, medication frequency （DDDs） and daily expenses （DDDc）, calculate the amount of sales order/DDDs sort precedence ratio analysis. Results Aromatase inhibitors and anti-estrogen drugs medication dominant position. DDDs are sorted before the five drugs：tamoxifen tablets, letrozole tablets （imported）, anastrozole tablets （imported）, sustained-release goserelin acetate implant, anastrozole tablets （Chongqing）. Conclusions It is reasonable to use endocrine drug on outpatient breast cancer in the hospital.
出处
《中国医药指南》
2014年第22期27-28,共2页
Guide of China Medicine
